- Home
- BCLI vs IMNN Comparison
BCLI vs IMNN Comparison
Compare BCLI & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- IMNN
- Stock Information
- Founded
- BCLI 2000
- IMNN 1982
- Country
- BCLI United States
- IMNN United States
- Employees
- BCLI N/A
- IMNN N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- BCLI Health Care
- IMNN Health Care
- Exchange
- BCLI Nasdaq
- IMNN Nasdaq
- Market Cap
- BCLI 13.5M
- IMNN 13.8M
- IPO Year
- BCLI N/A
- IMNN 1985
- Fundamental
- Price
- BCLI $1.89
- IMNN $0.91
- Analyst Decision
- BCLI Strong Buy
- IMNN Strong Buy
- Analyst Count
- BCLI 1
- IMNN 2
- Target Price
- BCLI $30.00
- IMNN $20.50
- AVG Volume (30 Days)
- BCLI 109.6K
- IMNN 425.6K
- Earning Date
- BCLI 11-14-2024
- IMNN 11-07-2024
- Dividend Yield
- BCLI N/A
- IMNN N/A
- EPS Growth
- BCLI N/A
- IMNN N/A
- EPS
- BCLI N/A
- IMNN N/A
- Revenue
- BCLI N/A
- IMNN N/A
- Revenue This Year
- BCLI N/A
- IMNN N/A
- Revenue Next Year
- BCLI N/A
- IMNN N/A
- P/E Ratio
- BCLI N/A
- IMNN N/A
- Revenue Growth
- BCLI N/A
- IMNN N/A
- 52 Week Low
- BCLI $1.05
- IMNN $0.48
- 52 Week High
- BCLI $11.85
- IMNN $3.65
- Technical
- Relative Strength Index (RSI)
- BCLI 44.80
- IMNN 52.89
- Support Level
- BCLI $1.90
- IMNN $0.84
- Resistance Level
- BCLI $2.17
- IMNN $1.08
- Average True Range (ATR)
- BCLI 0.18
- IMNN 0.08
- MACD
- BCLI -0.05
- IMNN -0.00
- Stochastic Oscillator
- BCLI 4.76
- IMNN 46.16
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About IMNN Imunon Inc.
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.